morning, Thanks, Juan. welcome call. Good to today's everyone, and
results and on first to pleased the quarter for are clinical XXXX of our share We updates provide studies. our to
Our bipolar depression strong team of current schizophrenia. growth in our continued for and indications CAPLYTA to deliver
we overwhelmingly XXX, results and label major CAPLYTA for choice disorder the positive drug major broad work a a expand of from as top mood into depressive as Study populations patient CAPLYTA's with established line to milestone With we achieved disorders.
about but more first, performance. let's this moment, talk in a commercial I'll start with our
Our strong growth continued.
million. to quarter total revenues $XXX.X increased First
the sales same CAPLYTA preannounced, net to growth increased XXXX. period in $XXX.X a versus we As representing million, XX%
We continued with are performance, CAPLYTA. the growth of pleased our in are we and confident
later of the million. Mark a will sales for call. year net $XXX $XXX reiterating in more our between million provide guidance are and Larry our performance full we detailed picture Consequently, and CAPLYTA
adjunctive month, robust XX. in most results to X results development treatment are These news. top we an shown antidepressants evaluating XXX, me highlight line recent lumateperone patients in MDD. clinical as Let with announced our from Study Slides positive Last through
X of at was than [indiscernible] on versus score less primary X.X from placebo study, X.XXXX the this impressive robust change with p-value the week total a adjunctive lumateperone The met X.XX. an conf baseline of with endpoint In MADRS reduction. size point
Statistically tested earliest you and measured were X, the as As continued these MADRS, point of the time seen the improvements significant depressive see, symptoms week at by trial. course reductions in can the throughout
the baseline Lumateperone of also endpoint p-value CGI-S the the tested less a a statistically met at improved change point than robust also and X.XXXX secondary of key size of from earliest with effect The time X. on CGI-S significantly week X.XX. clinician-rated
also a voice included clinician-rated of p-value or a to the self-report ], scale. than patient's CID scale symptoms. a of quick with depressive reduction the was There In measure in depressive this a symptoms the robust robust reduction symptomatology, less we X.XXXX. in [ their reported complement On study, of patient-reported patients measure inventory
We are the this that in improvements study. depressive patient the very endpoints in pleased reported clinician-rated symptoms support
demonstrating continue information and that changes depression and parameters, and placebo. We glucose, were safety and triglycerides as report including Today, profile. for and mean insulin, cholesterol lumateperone results favorable in safety lumateperone to studies LDL between the schizophrenia. we similar treatment key to HDL additional similar in pleased a of were seen tolerability those Adverse events to bipolar prior are see a of metabolic total
for Importantly, disorders. of Study lumateperone from similar changes spectrum underscore mood treat strong also XXX mean weight results broad in These placebo. a to were to potential the
exhibiting as comorbid bipolar patients mixed in strong program. II, shown bipolar patients both I and as antidepressant bipolar We a patients and lumateperone's as features in with adjunctive have MDD now adjunctive therapy MDD and our and patients with monotherapy in therapy in depression in an with with activity depression schizophrenia
disorders. the XXX, Study label long-term our and reinforced lumateperone's across strategy expansion mood pharmacology of distinct lumateperone coupled with results prospects The for
Phase second Study conduct. trial has III MDD completed XXX recently in clinical Our
expect disorder filing year, this to half highly expand drug later million we supplemental quarter. report to thus and a adults Subject application Study new the approximately is top anticipate large results, XXX second with from in of a already of opportunity the We to with results line the every bipolar a affected prevalent presenting XX on indications approved disorder. MDD XXXX. schizophrenia our FDA
annual as XX% Slide on MDD market indication increases approximately million prescriptions from for market approximately of CAPLYTA antipsychotic addressable bipolar of for XX% XX schizophrenia accounts antipsychotic MDD the indications. the with addition the and XX% seen total of annual XX, prescriptions. the to an nearly with market Therefore,
of possibility about for the option these treatment We patients. very are providing a new excited
provide with starting Let an programs. lumateperone pipeline, me now other update on our
pediatric lumateperone double-blind, spectrum schizophrenia placebo-controlled in and study irritability double-blind, disorder and disorder. study associated an autism a includes placebo-controlled depression bipolar Our studies bipolar program with in in open-label X safety
studies Patient in year. this enrollment bipolar placebo-controlled the study. of patient double-blind is quarter safety as as ongoing study disorder spectrum depression third enrollment in autism anticipate the well the in in the open-label We beginning
advance initiation long-acting to lumateperone with of continue we this Phase our formulations the additional with studies Additionally, I year. injectable later
ITI-XXXX programs, to lumateperone advance neuropsychiatry franchise. our continue we including other build We our and is candidate is continue duterated to as an a XXXX. pipeline important drug
the GAD. half note to This patient medications II with is adequately generalized in and million this effective, XX It offer ITI-XXXX or could to quarter, disorder, enrollment U.S. GAD.
There suited we safe well expect believe patients Phase in adjunctive approximately to with patient an clinical about respond of not in trial ITI-XXXX initiate therapy anxiety evaluating who received treatment therapy. anti-anxiety adults and as population initial for that well-tolerated treatment. important diagnosed our We are patients is through do
Phase Phase to clinical this well associated II Alzheimer's patient II as a in in plan with psychosis with as in quarter, disease associated we enrollment disease. initiate study later Also agitation study Alzheimer's
less phosphodiesterase program potent Our [ ] and inhibitor ITI-XXXX. lend X includes
Lumateperone Our II Parkinson's results ] XXXX. [ ongoing is top line in Phase are disease in and with study expected
recognition potent Besides to a motor key of inform ] nonmotor the symptom help improvement, and next effects steps. neuroinflammation disease in the line we manifestation of are of measuring biomarkers exploring [
second is ITI-XXXX, product developed indications. being candidate, for oncology Our PDEX
are I single ascending We a conducting currently TI-XXXX study with in volunteers. Phase dose healthy
ITI-XXX update disorder our and programs. earlier-stage to quick like exploring use We're on also to pain. opioid give I'd treat a
a Our dose study multiple and tomography ongoing. positron both emission study semi are
we the Finally, disorders. in a last and other [ portfolio expect neuropsychiatric can testing ] and for lead to ITI-XXXX, anxiety treatment nonvaluingenic is of preclinical mood, the psychedelic we begin introduced of clinical year, development, XXXX. date advancing
next be Psychiatry further A mechanism ITI-XXXX preclinical Meeting. described Biological scientific presented of of we poster novel describing Society at the advancement this of the Annual poster, In ITI-XXXX. the will action of week
of in reduction in improvement models and symptoms a demonstrate anhedonia also preclinical We anxiety. of
poster this information presentation. our We look forward to sharing following
$XXX.X a in maximize our million offering opportunities continue cash, quarter the us robust equivalents of to our from public and stock. with financial In proceeds million April ended CAPLYTA, and in are strong securities. We ahead gross position of with first we approximately pipeline. in the We to $XXX investment cash common XXXX, build we approximately received
have turn discuss Additionally, debt. further performance. the this Mark CAPLYTA now we no to Mark? I'll quarter's call over to
